CYDY
Conference call prevista para hoy a las 13:00 ET, que serán las 7 de la tarde aquí, para presentar updates...
VANCOUVER, Washington, May 22, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Nader Pourhassan, Ph.D., President and Chief Executive Officer, and Jacob Lalezari, M.D., Chief Science Officer, will host an investment community conference call on Tuesday, May 26, 2020 to provide a comprehensive update on several recent clinical and regulatory developments.
Management will dedicate approximately 30 minutes to address questions from analysts and investors.
Date: Tuesday, May 26, 2020
Time: 1:00 p.m. PT / 4:00 p.m. ET
Dial-In: 877-407-2986 US / 201-378-4916 International